Tammaryn Lashley

Mar 22, 2024 | nature.com | Fernando Gonzalez-Ortiz |Maciej Dulewicz |Vijay R. Varma |Tammaryn Lashley |Gunnar Brinkmalm |Susan M. Resnick | +6 more

AbstractBlood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer’s disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Here, we examined the diagnostic utility of plasma p-tau212.

Feb 14, 2024 | nature.com | Marian Hruska-Plochan |Vera I. Wiersma |Katharina M. Betz |Elena Tantardini |Florent Laferrière |Igor Delvendahl | +11 more

AbstractHuman cellular models of neurodegeneration require reproducibility and longevity, which is necessary for simulating age-dependent diseases. Such systems are particularly needed for TDP-43 proteinopathies1, which involve human-specific mechanisms2,3,4,5 that cannot be directly studied in animal models.

Dec 6, 2023 | nature.com | Stephan Tetter |Diana Arseni |Yazead Buhidma |Sew Y. Peak-Chew |Holly J. Garringer |Kathy L Newell | +3 more

AbstractFrontotemporal lobar degeneration (FTLD) causes frontotemporal dementia (FTD), the most common form of dementia after Alzheimer’s disease, and is often also associated with motor disorders1. The pathological hallmarks of FTLD are neuronal inclusions of specific, abnormally assembled proteins2. In the majority of cases the inclusions contain amyloid filament assemblies of TAR DNA-binding protein 43 (TDP-43) or tau, with distinct filament structures characterizing different FTLD subtypes3,4.

Dec 6, 2023 | pubs.acs.org | Thomas Enzlein |Tammaryn Lashley |Denis Abu Sammour |Carsten Hopf

Download Hi-Res ImageDownload to MS-PowerPointCite This:Anal. Chem. 2024, XXXX, XXXRETURN TO ARTICLES ASAPPREVArticleNEXTThomas EnzleinCenter for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack Str.

Jun 15, 2023 | mdpi.com | Ariana Gatt |Tammaryn Lashley |Xinwa Jiang

Abstract:Frontotemporal dementia (FTD) is the second most common form of young-onset (<65 years) dementia. Clinically, it primarily manifests as a disorder of behavioural, executive, and/or language functions. Pathologically, frontotemporal lobar degeneration (FTLD) is the predominant cause of FTD. FTLD is a proteinopathy, and the main pathological proteins identified so far are tau, TAR DNA-binding protein 43 (TDP-43), and fused in sarcoma (FUS).